Olaparix 150MG (Olaparib)
Product Name : Olaparix 150 mg (Olaparib)
Generic Name : Olaparib
Formulation : Tablet
Available Pack Size : 120s pot
Available Strengths : 150 mg
Registrations : 08.07.2021
Product Information
Olaparix (Olaparib) 150mg is a selective PARP1, PARP2, and PARP3 (Poly ADP-Ribose Polymerase) inhibitor used in the treatment of BRCA-mutated ovarian, breast, pancreatic, and prostate cancers in adult patients. It works by blocking the PARP-mediated DNA repair pathway in cancer cells that already carry a BRCA or homologous recombination repair (HRR) deficiency, driving those cells toward fatal levels of unrepaired DNA damage (synthetic lethality). Manufactured by Beacon Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Olaparix (Olaparib) 150mg
| Brand Name | Olaparix (Olaparib) |
| Generic Name | Olaparib INN |
| Drug Class | PARP Inhibitor (Poly ADP-Ribose Polymerase Inhibitor, PARP1/PARP2/PARP3) |
| Available Strength | 150mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 120 Tablets per Pot |
| Primary Indication | BRCA-Mutated Ovarian, Breast, Pancreatic and Prostate Cancer |
| Regulatory Approvals | USFDA Approved (Ovarian, Breast, Pancreatic and Prostate Cancer). EMA Approved (Ovarian and Breast Cancer). |
| Originator Brand | Lynparza by AstraZeneca and Merck |
| Manufacturer | Beacon Pharmaceuticals Ltd., Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Date | 08/07/2021 |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Olaparix (Olaparib) Works
Olaparix contains Olaparib, a potent inhibitor of the Poly ADP-Ribose Polymerase (PARP) enzyme family, including PARP1, PARP2, and PARP3. These enzymes play a central role in repairing single-strand DNA breaks inside cells. Cancer cells that carry a BRCA1 or BRCA2 mutation, or another defect in the homologous recombination repair (HRR) pathway, already rely heavily on the PARP repair route to survive.
By trapping PARP enzymes on damaged DNA and blocking their repair function, Olaparib prevents BRCA-deficient cancer cells from repairing themselves. The accumulated DNA damage is eventually converted into double-strand breaks that the cancer cell cannot fix, leading to cell death through a mechanism known as synthetic lethality. Healthy cells with functioning BRCA genes are far less affected, giving Olaparib a targeted mode of action against tumour cells.
Olaparix is administered as a convenient oral tablet, taken twice daily, offering patients an effective alternative or complement to intravenous chemotherapy regimens in BRCA-mutated cancers.
Indications for Olaparix (Olaparib)
Olaparix (Olaparib) is indicated for the following BRCA-mutated and HRR-deficient cancers:
|
Ovarian, Fallopian Tube and Peritoneal Cancer Maintenance treatment of adult patients with BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy, used as monotherapy or in combination with bevacizumab in HRD-positive disease. |
Breast Cancer Adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer following neoadjuvant or adjuvant chemotherapy, and treatment of germline BRCA-mutated, HER2-negative metastatic breast cancer previously treated with chemotherapy. |
|
Pancreatic Cancer Maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least sixteen weeks of first-line platinum-based chemotherapy. |
Prostate Cancer Treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), as monotherapy following prior therapy, or in combination with abiraterone and prednisone/prednisolone. |
Benefits of Olaparix (Olaparib) 150mg
|
Oral Targeted Therapy Olaparix offers a convenient tablet-based targeted therapy for BRCA-mutated cancers, reducing reliance on repeated hospital visits for intravenous chemotherapy infusions. |
Multi-Cancer Approved Indications Approved across ovarian, breast, pancreatic, and prostate cancers with a BRCA mutation or HRR deficiency, making Olaparix a versatile PARP inhibitor across multiple oncology settings. |
Extended Progression-Free Survival In pivotal clinical trials, Olaparib maintenance therapy demonstrated significantly longer progression-free survival compared to placebo in BRCA-mutated ovarian and other cancers. |
|
Affordable Alternative to Lynparza Olaparix contains the same active ingredient as Lynparza by AstraZeneca and Merck, at a significantly lower cost, making long-term oncology treatment more financially accessible. |
Combination Therapy Compatible Olaparix can be used as monotherapy or in combination with bevacizumab in ovarian cancer, or with abiraterone and prednisone in prostate cancer, giving oncologists flexibility in treatment planning. |
WHO-GMP and cGMP Certified Produced by Beacon Pharmaceuticals Ltd. under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards, ensuring every batch of Olaparix meets consistent quality, safety, and efficacy requirements. |
How to Take Olaparix (Olaparib)
Route: Oral, taken by mouth
Standard dose (all approved indications): 300mg (two 150mg tablets) taken twice daily, for a total daily dose of 600mg. Tablets should be swallowed whole and not chewed, crushed, dissolved, or divided.
With food: Can be taken with or without food, at any time of the day
Companion diagnostic testing: BRCA mutation or HRD status should be confirmed with an approved companion diagnostic test before starting Olaparix, in line with the specific cancer type being treated.
Dose adjustments: Dose reductions may be required for adverse reactions, moderate renal impairment, or unavoidable coadministration with CYP3A inhibitors. Any change to dose or schedule must be individualised and supervised by the prescribing oncologist.
Renal impairment: No adjustment is needed for mild renal impairment. Use with caution and closer monitoring in moderate renal impairment. Olaparix is not recommended in patients with severe renal impairment or end-stage renal disease due to limited data.
Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment. Olaparix has not been studied in patients with severe hepatic impairment.
CYP3A interactions: Avoid coadministration with strong or moderate CYP3A inhibitors or inducers where possible, as these significantly alter Olaparib plasma exposure. If unavoidable, dosing must be adjusted by the prescribing physician.
Paediatric use: The safety and efficacy of Olaparix in children and adolescents have not been established. No data are currently available.
Monitoring and Dosage Adjustments
Regular monitoring is essential during Olaparix treatment. Your oncologist will monitor complete blood counts at baseline and monthly thereafter to detect early signs of myelosuppression, myelodysplastic syndrome, or acute myeloid leukaemia. Monitoring also includes renal function, watching for signs of pneumonitis such as new or worsening shortness of breath, cough, or fever, and signs of venous thromboembolism. Report any unexplained bruising, prolonged fatigue, breathlessness, or leg swelling to your doctor immediately.
Drug Interactions and Important Information
Avoid concomitant use of Olaparix with other myelosuppressive anticancer agents, as combined use may potentiate and prolong bone marrow suppression.
Avoid strong or moderate CYP3A inhibitors (including certain antifungals, macrolide antibiotics, and grapefruit or Seville orange products) and strong or moderate CYP3A inducers during treatment, as these substantially change Olaparib blood levels. Always inform your oncologist of all medications, supplements, and herbal products you are currently taking before starting Olaparix.
Side Effects and Precautions
|
Common Side Effects Nausea and vomiting Fatigue and asthenia Anaemia Diarrhoea Decreased appetite Headache Taste alteration (dysgeusia) Low white blood cell or platelet counts |
Serious Warnings and Precautions Myelodysplastic syndrome and acute myeloid leukaemia (MDS/AML), which can be fatal. Requires baseline and monthly blood count monitoring. Pneumonitis. Report new or worsening cough, fever, or breathlessness immediately. Venous thromboembolism (VTE) including deep vein thrombosis and pulmonary embolism. Embryo-fetal toxicity. Contraindicated in pregnancy; effective contraception required during and after treatment. Not recommended during breastfeeding. Not recommended in patients with severe renal or hepatic impairment. |
Who Should Use Olaparix (Olaparib)?
Olaparix is suitable for adult patients with a confirmed BRCA mutation or homologous recombination repair (HRR) deficiency in the setting of advanced ovarian, fallopian tube or peritoneal cancer, high-risk early or metastatic HER2-negative breast cancer, metastatic pancreatic adenocarcinoma, or metastatic castration-resistant prostate cancer. It is prescribed and supervised by oncologists as part of a comprehensive cancer treatment plan. A thorough medical assessment including BRCA/HRD companion diagnostic testing, full blood counts, and renal and hepatic function is required before initiating treatment.
Manufacturer: Beacon Pharmaceuticals Ltd.
Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards. Olaparix is one of Beacon’s globally recognised oncology products, offering an affordable and bioequivalent alternative to Lynparza at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Olaparix (Olaparib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Olaparix (Olaparib) from Mediaid Pharmacy?
Olaparix represents an important treatment option for patients with BRCA-mutated and HRR-deficient cancers. As the generic equivalent of Lynparza by AstraZeneca and Merck, it delivers the same active ingredient, Olaparib, with the same proven PARP-inhibiting mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Olaparix gives patients worldwide access to high-quality targeted oncology therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Olaparib option with worldwide delivery, Olaparix from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Olaparix (Olaparib)
What is Olaparix (Olaparib) used for?
Olaparix (Olaparib) is a PARP inhibitor used in the treatment of BRCA-mutated advanced ovarian cancer, HER2-negative breast cancer, metastatic pancreatic adenocarcinoma, and metastatic castration-resistant prostate cancer in adults. It works by blocking a DNA repair pathway that BRCA-deficient cancer cells rely on, causing those cells to die while sparing healthy cells.
How should I take Olaparix (Olaparib)?
Olaparix is taken orally, with the standard dose being 300mg (two 150mg tablets) twice daily, with or without food, for all approved indications. Tablets should be swallowed whole. Dose adjustments may be required for adverse reactions, renal impairment, or interacting medications, and must always be directed by your prescribing oncologist.
What strength is Olaparix (Olaparib) available in?
Olaparix is available as a 150mg film-coated tablet, supplied in a pot of 120 tablets. The standard 300mg twice-daily dose is achieved by taking two 150mg tablets per dose.
Is Olaparix the same as Lynparza (Olaparib by AstraZeneca)?
Yes. Olaparix is the generic equivalent of Lynparza. Both contain the same active ingredient, Olaparib, in the same dosage form and strength. Olaparix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and delivers the same clinical benefits as Lynparza at a significantly lower cost, making it a more accessible option for patients worldwide.
What are the side effects of Olaparix (Olaparib)?
Common side effects include nausea, fatigue, anaemia, vomiting, diarrhoea, decreased appetite, headache, and taste changes. Serious but less common risks include myelodysplastic syndrome/acute myeloid leukaemia, pneumonitis, venous thromboembolism, and embryo-fetal toxicity. Always consult your oncologist for a complete assessment of your individual risks and benefits before starting treatment.
Does Olaparix require BRCA testing before use?
Yes. Olaparix should only be used in patients whose BRCA mutation or HRR/HRD status has been confirmed with an approved companion diagnostic test appropriate to their cancer type. This ensures the medicine is directed to patients most likely to benefit from PARP inhibition.
Is Olaparix (Olaparib) safe during pregnancy or breastfeeding?
No. Olaparix is contraindicated during pregnancy due to the risk of embryo-fetal toxicity, and is not recommended during breastfeeding. Women of childbearing potential must use effective contraception during treatment and for a period after the final dose. Please consult your oncologist before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Olaparix (Olaparib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Olaparix (Olaparib) 150mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Olaparix (Olaparib) 150mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
